author-photo

Xuewei Cui

Eli Lilly and Company

11

Papers

591

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens

2020 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (40)
The Novel Dual GIP and GLP‐1 Receptor Agonist, Tirzepatide, Transiently Delays Gastric Emptying Similarly to Selective Long‐Acting GLP‐1 Receptor Agonists

2020 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (4)
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes.

2020 The Journal of Clinical Endocrinology and Metabolism
Show All
- Source
- Cite
- Save
Citations (20)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

2018 Molecular metabolism
Show All
- Source
- Cite
- Save
Citations (146)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

2018 The Lancet
Show All
- Source
- Cite
- Save
Citations (286)
No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide

2017 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (6)
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials

2016 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (33)